RecruitingNCT04688190
CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry
Choice of Optimal Transcatheter Treatment for Mitral Insufficiency Registry
Sponsor
Universitätsklinikum Hamburg-Eppendorf
Enrollment
800 participants
Start Date
Nov 1, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
This multinational, investigator-initiated, retrospective study aims to investigate outcomes of patients, who underwent transcatheter mitral valve implantation (TMVI), in comparison to those screened for TMVI but deemed ineligible, who subsequently underwent interventional mitral valve edge-to-edge repair, mitral valve surgery or medical/conservative therapy.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- clinically significant mitral insufficiency
- patient underwent screening for TMVI
- echocardiography data at baseline (and after TMVI, E2E and surgery)
- follow-up of at least 30 days
Exclusion Criteria1
- \- age under 18 years
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(26)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04688190
Related Trials
A Clinical Study of GeminiOne TEER System for the Treatment of Severe, Symptomatic MR.
NCT070865341 location
Cephea Early Feasibility Study
NCT0506100422 locations
Abbott Cephea Mitral Valve Disease Registry
NCT0706967319 locations
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant
NCT070071431 location
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant
NCT069014661 location